Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) reached a new 52-week high on Tuesday . The stock traded as high as $44.48 and last traded at $44.27, with a volume of 8257 shares changing hands. The stock had previously closed at $43.15.
Several equities research analysts recently weighed in on BHVN shares. Zacks Investment Research downgraded Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, October 16th. Cantor Fitzgerald set a $57.00 target price on Biohaven Pharmaceutical and gave the stock a “buy” rating in a report on Thursday, October 18th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $65.00 target price on shares of Biohaven Pharmaceutical in a report on Wednesday, October 24th. Oppenheimer began coverage on Biohaven Pharmaceutical in a report on Monday, November 12th. They set a “buy” rating and a $63.00 target price on the stock. Finally, Leerink Swann began coverage on Biohaven Pharmaceutical in a report on Monday, November 12th. They set an “outperform” rating and a $50.00 target price on the stock. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $51.33.
The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of -8.78 and a beta of 0.38.
Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Wednesday, November 14th. The company reported ($1.53) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.48). Research analysts anticipate that Biohaven Pharmaceutical Holding Co Ltd will post -6.05 EPS for the current fiscal year.
In related news, insider John Tilton sold 10,500 shares of the business’s stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $37.67, for a total value of $395,535.00. Following the completion of the sale, the insider now directly owns 10,500 shares of the company’s stock, valued at approximately $395,535. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 34.20% of the company’s stock.
A number of institutional investors have recently modified their holdings of BHVN. Bank of America Corp DE increased its position in Biohaven Pharmaceutical by 34.9% in the 2nd quarter. Bank of America Corp DE now owns 128,367 shares of the company’s stock valued at $5,073,000 after buying an additional 33,215 shares in the last quarter. California Public Employees Retirement System bought a new stake in Biohaven Pharmaceutical in the 2nd quarter valued at about $790,000. Bank of New York Mellon Corp increased its position in Biohaven Pharmaceutical by 16.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 141,762 shares of the company’s stock valued at $5,603,000 after buying an additional 20,364 shares in the last quarter. Northern Trust Corp increased its position in Biohaven Pharmaceutical by 6.6% in the 2nd quarter. Northern Trust Corp now owns 323,923 shares of the company’s stock valued at $12,802,000 after buying an additional 20,093 shares in the last quarter. Finally, United Services Automobile Association increased its holdings in Biohaven Pharmaceutical by 20.1% during the 2nd quarter. United Services Automobile Association now owns 16,420 shares of the company’s stock worth $649,000 after purchasing an additional 2,743 shares in the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Zolmax and is the property of of Zolmax. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://zolmax.com/investing/biohaven-pharmaceutical-bhvn-sets-new-1-year-high-at-44-48/2894762.html.
About Biohaven Pharmaceutical (NYSE:BHVN)
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.